TY - JOUR
T1 - Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4
AU - Takeuchi, Ario
AU - Kamiryou, Yoriyuki
AU - Yamada, Hisakata
AU - Eto, Masatoshi
AU - Shibata, Kensuke
AU - Haruna, Kennichi
AU - Naito, Seiji
AU - Yoshikai, Yasunobu
N1 - Funding Information:
This work was supported by the Program of Founding Research Centers for Emerging and Reemerging Infectious Disease and was launched as a project commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan by a Grant-in-Aid for Japan Society for Promotion of Science, and grants from the Japanese Ministry of Education, Science and Culture (Y.Y.).
PY - 2009/12
Y1 - 2009/12
N2 - Purpose: Xanthan gum (XG) is a complex exopolysaccharide produced by the plant-pathogenic bacterium Xanthomonas campestris pv. and is widely used as a thickener or viscosifier. We examined in this study the antitumor effects of XG. Experimental design: Cytokine production by XG-stimulated murine macrophage cell lines, J772 and RAW264.7, and peritoneal adherent cells from wild type C57BL/6 mice, TLR2 or MyD88-deficient mice, C3H/HeN, and TLR4-mutant C3H/HeJ mice were examined. In order to examine in vivo antitumor effects of XG, mice were inoculated subcutaneously with tumor cells and administered orally with XG once every 5 days from 1 day before the tumor inoculation. Tumor growth, mouse survival, NK activity, and tumor-specific cytotoxicity were examined. Results: In vitro culture with XG induced interleukin-12 and tumor necrosis factor-alpha production from macrophages. XG stimulated macrophages in a MyD88-dependent manner and was mainly recognized by Toll-like receptor 4 (TLR4). Oral administration of XG significantly retarded tumor growth and prolonged survival of the mice inoculated subcutaneously with B16Kb melanoma cells. NK activity as well as tumor-specific cytotoxicity of CD8 T cells was augmented in the XG-treated mice. The in vivo antitumor effects of XG were also dependent on TLR-4, as C3H/HeJ mice, which lack TLR4 signaling, exhibited no effect of XG on the growth of syngeneic bladder tumor, MBT-2. Conclusion: These results suggest beneficial effects of oral administration of XG on immune-surveillance against neoplasms.
AB - Purpose: Xanthan gum (XG) is a complex exopolysaccharide produced by the plant-pathogenic bacterium Xanthomonas campestris pv. and is widely used as a thickener or viscosifier. We examined in this study the antitumor effects of XG. Experimental design: Cytokine production by XG-stimulated murine macrophage cell lines, J772 and RAW264.7, and peritoneal adherent cells from wild type C57BL/6 mice, TLR2 or MyD88-deficient mice, C3H/HeN, and TLR4-mutant C3H/HeJ mice were examined. In order to examine in vivo antitumor effects of XG, mice were inoculated subcutaneously with tumor cells and administered orally with XG once every 5 days from 1 day before the tumor inoculation. Tumor growth, mouse survival, NK activity, and tumor-specific cytotoxicity were examined. Results: In vitro culture with XG induced interleukin-12 and tumor necrosis factor-alpha production from macrophages. XG stimulated macrophages in a MyD88-dependent manner and was mainly recognized by Toll-like receptor 4 (TLR4). Oral administration of XG significantly retarded tumor growth and prolonged survival of the mice inoculated subcutaneously with B16Kb melanoma cells. NK activity as well as tumor-specific cytotoxicity of CD8 T cells was augmented in the XG-treated mice. The in vivo antitumor effects of XG were also dependent on TLR-4, as C3H/HeJ mice, which lack TLR4 signaling, exhibited no effect of XG on the growth of syngeneic bladder tumor, MBT-2. Conclusion: These results suggest beneficial effects of oral administration of XG on immune-surveillance against neoplasms.
UR - http://www.scopus.com/inward/record.url?scp=70350564316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350564316&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2009.09.012
DO - 10.1016/j.intimp.2009.09.012
M3 - Article
C2 - 19788935
AN - SCOPUS:70350564316
VL - 9
SP - 1562
EP - 1567
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 13-14
ER -